Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology Summit May 22, 2025

Show notes

Featuring perspectives from Dr Shilpa Gupta and Dr Jonathan E Rosenberg, including the following topics:

Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta (0:00)
Optimizing the Treatment of Metastatic UBC — Dr Rosenberg (21:52)

CME information and select publications

Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit May 21, 2025

Show notes

Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics:

Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00)
Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57)

CME information and select publications

Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies May 20, 2025

Show notes

Featuring an interview with Dr Jennifer Crombie, including the following topics:

Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00)
Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40)
Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52)
Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46)
Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06)
Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19)

CME information and select publications

5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer May 19, 2025

Show notes

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00)
- Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract
- Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01.
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00)
- Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract
Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25)
- Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract
Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57)
- Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5.

CME information and select publications

Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit May 18, 2025

Show notes

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics:

Introduction (0:00)
Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04)
First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59)

CME information and select publications

Colorectal Cancer — Fourth Annual National General Medical Oncology Summit May 17, 2025

Show notes

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics:

Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00)
Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58)

CME information and select publications

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy May 16, 2025

Show notes

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00)
Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50)
Published Clinical Data Involving Axi-cel (10:24)
Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34)
Published Clinical Data Involving Tis-cel (19:47)
Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43)
Published Clinical Data Involving Liso-cel (26:05)
Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48)
Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35)
Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59)

CME information and select publications

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances May 15, 2025

Show notes

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics:

Introduction: Quality of Life (0:00)
PARP Inhibition (PARPi) (7:15)
M0 Disease (23:18)
Metastatic Hormone-Sensitive Prostate Cancer (34:33)
Radiopharmaceuticals (46:16)
Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53)

CME information and select publications

Prostate Cancer | Emmanuel S Antonarakis, MD May 14, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Emmanuel S Antonarakis, MD

CME information and select publications

Prostate Cancer | Professor Karim Fizazi, MD, PhD May 13, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer (PC) — Professor Karim Fizazi, MD, PhD

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected